ClinicalTrials.gg
Active, not recruitingNCT04294004STRUCTUREUpdated Aug 9, 2023

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

A Phase 2 interventional study of TGplPTH1-34 in fibrin and Autologous Bone Graft in Degenerative Disc Disease and Spinal Fusion, sponsored by Kuros Biosurgery AG. Active, not recruiting at 15 sites in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Kuros Biosurgery AG · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
74th of 141
50 · median 57
Started
2020
with 16 others
Phase 2
10 of 232
none open now
Primary completion
2024-07
later than 1 of 57 live
Registered
155th of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 74th largest by enrollment of the 141 interventional ones that give a count, is one of 17 that started in 2020, is one of 10 in phase 2, reaches primary completion later than 1 of the 57 other live ones, and was the 155th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) compared to local autograft for the treatment of Degenerative Disk Disease (DDD).

Read the detailed description

Degenerative disc disease (DDD) is a common disorder of the lumbar spine. Clinically, DDD causes discogenic back pain and may cause related radicular, neuropathic, claudicatory, and referred pain.

This is a prospective, randomized and non-randomized, controlled, single-blind and open-label, dose-finding, multi-center study which intends to demonstrate the safety and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft. The study will enroll 50 patients with Degenerative Disk Disease (DDD) requiring single-level interbody fusion along with posterolateral fusion (PLF) with posterior fixation who meet eligibility criteria and agree to participate in the study. Safety and efficacy of KUR-113 Bone Graft will be evaluated by analyzing all clinical as well as radiological endpoints and adverse events. This phase 2a study is not powered to detect non-inferiority. All patients will undergo clinical and radiological assessments at initial hospital discharge (on average 3 days post-surgery), 6 weeks, 3, 6, 12 and 24 months.

03

Conditions studied

  • Degenerative Disc Disease
  • Spinal Fusion

Keywords

  • Spinal Fusion
  • Posterolateral Fusion
  • MagnetOs
  • Fibrin-PTH (KUR-113)
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written by the patient.
  2. Male or female patient ≥ 25 up to and including 75 years old. Females of with a negative urine pregnancy test at Screening. Females of childbearing potential must agree to use acceptable for at least 12 months after surgery and product placement.
  3. Patients with degenerative disc disease with up to grade 1 spondylolisthesis and with leg pain requiring up to 3 levels of laminectomy/decompression and a single-level fusion (L2 - S1). DDD is defined by the presence of one or more of the following:

    1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
    2. osteophyte formation of facet joints or vertebral endplates,
    3. decreased disc height by > 2 mm, but dependent upon the spinal level,
    4. scarring/thickening of ligamentum flavum, annulus fibrosis or facet joint capsule,
    5. disc degeneration and/or herniation,
    6. facet degeneration,
    7. vacuum phenomenon.
  4. Patients with an Oswestry Disability Index (ODI) score ≥ 35.
  5. Patients with a Visual Analogue Scale (VAS) leg score ≥ 40.
  6. Failed conservative treatment (physical therapy, bed rest, medications, spinal injections or transcutaneous electrical nerve stimulation) for a period of 6 months prior to study enrollment.
  7. Patients willing to undergo PK sampling.

Exclusion criteria

Exclusion Criteria:

  1. Patients with open epiphyseal plates.
  2. Patient requiring emergency spinal decompression or spinal fusion.
  3. Patients requiring multilevel fusion or expected to need secondary intervention within one year following surgery.
  4. Any prior fusion or attempted fusion at an adjacent level.
  5. Any prior fusion or attempted fusion at the index level.
  6. Pregnant or breast-feeding women.
  7. Known or suspected allergies to any of the components of KUR-113 Bone Graft (e.g.

    to aprotinin).

  8. Any prior use of teriparatide or abaloparatide or graft material containing PTH1-34.
  9. Patients with hypercalcemic disorders (e.g., primary hyperparathyroidism).
  10. Patients with Paget's Disease or unexplained high levels of alkaline phosphatase.
  11. Prior radiation therapy involving bone.
  12. Medical history or radiographic evidence of a metabolic bone disorder (e.g. Paget's Disease) or other condition that would negatively impact the healing process.
  13. Any medical condition requiring radiotherapy or .
  14. History of thyroid disease (Hashimoto's thyroiditis, Graves' disease) or hyperthyroidism.
  15. Patients on chronic systemic (i.e. > 14 consecutive days) within 6 months prior to Screening Visit.
  16. Osteopenia (T score \< -1.0) or osteoporosis of the spine (T score \< -2.5).
  17. DDD related to benign or malignant tumor.
  18. History or presence of active .
  19. Hereditary disorders predisposing to osteosarcoma.
  20. Patients with invasive skin cancer.
  21. Evidence of local or systemic infection.
  22. Patients with known active COVID-19 disease.
  23. Current smokers.
  24. Type 1 diabetes (regardless of ) or Type 2 diabetes with a documented HbA1c > 7.0.
  25. Any acute or chronic concurrent medical conditions that in the Investigator's opinion are a to the procedure and study participation.
  26. Participation in another study within 30 days prior to surgery for investigational devices, or within the last three months for investigational drugs. (Note: trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).
  27. Known substance abuse, psychiatric disorder or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
  28. Involved in active litigation relating to his/her spinal condition or workers compensation claimants.
  29. greater than 40.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    KUR-113, Stage 1

    During stage 1, subjects randomized to this arm will receive TGplPTH1-34 in fibrin (0.4mg/ml) that will be applied within and around a polyetheretherketone (PEEK) intervertebral cage. The maximum dose that will be applied is 4 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.

    Combination Product: TGplPTH1-34 in fibrin

  • Active comparator
    Autologous Bone Graft

    During stage 1 of the study, subjects randomized to this arm will receive local autologous bone graft. In the event of insufficient local autograft, Iliac crest bone graft may be used to supplement.

    Other: Autologous Bone Graft

  • Experimental
    KUR-113, Stage 2

    During stage 2, subjects will receive TGplPTH1-34 in fibrin that will be applied within and around a PEEK intervertebral cage at a concentration of 0.7mg/ml. The concentration received was selected by the DSMB based on the results of stage 1. The maximum dose that will be applied is 7 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.

    Combination Product: TGplPTH1-34 in fibrin

Interventions

  • Combination productTGplPTH1-34 in fibrin

    TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage

    Also known as: KUR-113

  • OtherAutologous Bone Graft

    Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.

06

What researchers measure

Primary outcomes

  1. Radiographic interbody fusion

    Evidence of bridging trabeculae or continuous bony connection between superior and inferior vertebral body on CT-scan as determined by an independent radiology expert panel (IREP).

    Time frame: Month 12 post-surgery

Secondary outcomes

  1. Composite Endpoint

    Radiographic interbody fusion using CT-scans, functional outcome (decrease of 15 points or more on Oswestry Disability Index (ODI)) and no post-surgical intervention to aid fusion or replace any of the spinal implants.

    Time frame: Month 6 and Month 12 post-surgery

  2. Radiographic interbody fusion

    Determined by IREP using CT-scans

    Time frame: Month 6 post-surgery

  3. Radiographic posterolateral fusion

    Determined by IREP using CT-scans

    Time frame: Month 6 and Month 12 post-surgery

  4. ODI

    Change from baseline

    Time frame: Week 6, Month 3, Month 6, Month 12, and Month 24 post-surgery

  5. Leg Pain

    Change from baseline using Visual Analogue Scale (VAS). VAS is scored from 0 to 100 with higher numbers being a worse outcome than a lower number.

    Time frame: Initial discharge from hospital (on average 3 days post-surgery), Week 6, Month 3, Month 6, Month 12, and Month 24 post-surgery

  6. Back Pain

    Change from baseline using Visual Analogue Scale (VAS). VAS is scored from 0 to 100 with higher numbers being a worse outcome than a lower number.

    Time frame: Initial discharge from hospital (on average 3 days post-surgery), Week 6, Month 3, Month 6, Month 12, and Month 24 post-surgery

  7. Number of Secondary Interventions

    Revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or in any way removes part of the original implant configuration with or without replacement of the components

    Time frame: Up to Month 24 post-surgery

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Jul 2024, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2020
First posted
Mar 3, 2020
StartActual
Aug 27, 2020
Primary completionEst.
Jul 30, 2024
CompletionEst.
Jul 30, 2025
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04294004
Lead sponsor
Kuros Biosurgery AG
Collaborators
Avania, Kuros BioSciences B.V.
Responsible party
Sponsor
First posted
Mar 3, 2020
Start date
Aug 27, 2020
Primary completion
Jul 30, 2024 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Aug 9, 2023

Study contacts

John Chi, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion